Market News
- Going Beyond Visuals to Connect with Diverse Audiencesby OncLive articles on April 26, 2024
In this Pharmaceutical Executive video interview, Amanda Powers-Han, Chief Marketing Officer, Greater Than One, discusses what other tactics healthcare marketers can utilize to connect with diverse audiences on a deeper level
- Pfizer hemophilia gene therapy arrives in US to uncertain futureby Ben Fidler (BioPharma Dive – Latest News) on April 26, 2024
The Food and Drug Administration approval of Beqvez comes as other gene therapies for the bleeding condition that were approved earlier struggle to gain traction.
- Merck’s net income for Q1 2024 increases by 69% to $4.76bnby Archana Rani (Pharmaceutical Technology) on April 26, 2024
Merck has reported a significant increase in net income attributable to shareholders, reaching $4.76bn in Q1 2024, a 69% rise from $2.82bn in the same period last year.
- Multiply Labs and GenScript partner on cell isolation automationby Archana Rani (Pharmaceutical Technology) on April 26, 2024
Robotics company Multiply Labs has partnered with global life-sciences service provider GenScript Biotech to automate the cell isolation phase in cell therapy manufacturing.
- BioAro Announces Real Time DNA Decoding Technologyby OncLive articles on April 26, 2024
PanOmiQ is referred to as the fasted technology of its kind by the company.
- Solving the First Mile Problem: Q&A with Mark Meltonby OncLive articles on April 26, 2024
Melton, customer advocacy executive at Magnolia, discusses how new technologies can be used to ensure data is accurate.
- CVS Health Announces New Work Force Development and Community Center in Louisianaby OncLive articles on April 26, 2024
The center will offer local residents with opportunities and training to enter the pharmacy work force.
- Pharma Pulse 4/26/24: 20 States Select Direct Care Workforce Enhancement Programs by HHS, Do Assigned Roles in Clinical Trials Affect Patient-Reported Outcomes? & moreby OncLive articles on April 26, 2024
The latest news for pharma industry insiders.
- Regeneron and Mammoth team up to develop gene editing therapiesby Archana Rani (Pharmaceutical Technology) on April 26, 2024
Regeneron Pharmaceuticals has collaborated with Mammoth Biosciences to develop in vivo clustered regularly interspaced short palindromic repeats (CRISPR)-based gene editing therapies.
- AstraZeneca posts $2.18bn profit after tax in Q1 2024by Archana Rani (Pharmaceutical Technology) on April 26, 2024
AstraZeneca has reported profit after tax of $2.18bn for the first quarter (Q1) of 2024, a notable rise from $1.80bn reported in the same period last year.
- Sanders takes aim at US drug prices of Novo’s Ozempic and Wegovyby Justine Ra (Pharmaceutical Technology) on April 25, 2024
A Senate Committee is investigating the “outrageously high” US price tags of the blockbuster diabetes and obesity drugs.
- AstraZeneca’s earnings surprise investors as cancer drugs fuel growthby Jonathan Gardner (BioPharma Dive – Latest News) on April 25, 2024
The British drugmaker has bolstered its business with nearly $5 billion in acquisitions as attention turns to its pipeline of experimental medicines.
- Novartis, Medicines for Malaria Venture Release Positive Results from Phase II/III Trial of Coartem for Infants with Malariaby OncLive articles on April 25, 2024
Companies reported that the new formulation of Coartem met required pharmacokinetic profiles and displayed promising efficacy and safety treating malaria in infants.
- FDA Approves Utility Therapeutics’ Pivya to Treat Uncomplicated Urinary Tract Infections in Adult Femalesby OncLive articles on April 25, 2024
Pivya has shown efficacy against bacteria strains such as Escherichia coli, Proteus mirabilis, and Staphylococcus saprophyticus.
- Cidara buys back rights to flu therapy from J&J for $85mby Phalguni Deswal (Pharmaceutical Technology) on April 25, 2024
Marking another chapter in the long-running saga, J&J has deprioritised the CD388 influenza programme allowing Cidara to buy it back.
- Inflation Reduction Act to have knock on effect on R&D, say biotech experts by Jenna Philpott (Pharmaceutical Technology) on April 25, 2024
As the Biden Administration faces lawsuits from pharma companies, industry experts discuss the impact of the Inflation Reduction Act on R&D.
- BioMarin drops drug programs in pipeline cullby Kristin Jensen (BioPharma Dive – Latest News) on April 25, 2024
The cuts of four pipeline prospects come as BioMarin resets its priorities following the slow launch of its hemophilia gene therapy Roctavian.
- Bernie Sanders Announces Investigation into Ozempic and Wegovy Pricingby OncLive articles on April 25, 2024
Sanders wrote a letter to Novo Nordisk announcing the investigation.
- Crafting Culturally Sensitive Messages to Reach Diverse Audiences and Improve Patient Outcomesby OncLive articles on April 25, 2024
In this Pharmaceutical Executive video interview, Amanda Powers-Han, Chief Marketing Officer, Greater Than One, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but address […]
- Bristol Myers to cut 6% of workforce, trim drug pipelineby Ned Pagliarulo (BioPharma Dive – Latest News) on April 25, 2024
The layoffs will impact some 2,200 employees, the company said, as it repositions ahead of looming patent expirations for top-selling products.